SOURCE-LINKED STUDY SUMMARY
Evaluation of Research Grade Peptides Marketed Directly to Consumers Reveals Extensive Variability in Purity and Measured Abundance
What was studied?
This preprint analyzed an independent public testing dataset to assess purity, measured peptide abundance, and endotoxin contamination in gray-market research peptides, and compared costs with pharmaceutical alternatives.
What changed?
Using two quality frameworks modeled on compounded-drug and approved-peptide standards, 41.6% to 71.1% of samples failed the applied criteria. Measurable endotoxin was reported in 15%. Gray-market products cost less, but this did not establish safety.
Who was studied?
The dataset contained 6441 samples across fourteen compounds, including BPC-157, cagrilintide, CJC-1295, GHK-Cu, retatrutide, semaglutide, and tirzepatide. These were product samples, not treated patients.
Studied exposure
Not extracted or not reported in this source.
What remains uncertain?
The authors caution that consumer-directed third-party testing captures only a small fraction of the safety profile relevant to people injecting these preparations.
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.20944/preprints202604.1748.v1